Articles with public access mandates - Rachana PatelLearn more
Not available anywhere: 1
Targeting the EGFR-family for therapy: biological challenges and clinical perspective
R Patel, H Y Leung
Current pharmaceutical design 18 (19), 2672-2679, 2012
Mandates: Cancer Research UK
Available somewhere: 24
Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments
B Peck, ZT Schug, Q Zhang, B Dankworth, DT Jones, E Smethurst, ...
Cancer & metabolism 4, 1-18, 2016
Mandates: US National Institutes of Health, German Research Foundation, UK …
2, 4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
A Blomme, CA Ford, E Mui, R Patel, C Ntala, LE Jamieson, M Planque, ...
Nature Communications 11 (1), 2508, 2020
Mandates: Research Foundation (Flanders), Cancer Research UK, UK Engineering and …
Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer
I Ahmad, E Mui, L Galbraith, R Patel, EH Tan, M Salji, AG Rust, ...
Proceedings of the National Academy of Sciences 113 (29), 8290-8295, 2016
Mandates: Cancer Research UK, UK Medical Research Council
Plakophilin3 downregulation leads to a decrease in cell adhesion and promotes metastasis
ST Kundu, P Gosavi, N Khapare, R Patel, AS Hosing, GB Maru, A Ingle, ...
International journal of cancer 123 (10), 2303-2314, 2008
Mandates: US National Institutes of Health
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression
R Patel, M Gao, I Ahmad, J Fleming, LB Singh, TS Rai, AB McKie, ...
The Journal of clinical investigation 123 (3), 1157-1175, 2013
Mandates: Cancer Research UK
Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis
I Ahmad, R Patel, Y Liu, LB Singh, MM Taketo, XR Wu, HY Leung, ...
Cell death & disease 2 (3), e124-e124, 2011
Mandates: Cancer Research UK
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
I Ahmad, R Patel, LB Singh, C Nixon, M Seywright, RJ Barnetson, ...
Proceedings of the National Academy of Sciences 108 (39), 16392-16397, 2011
Mandates: Cancer Research UK
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis
M Gao, R Patel, I Ahmad, J Fleming, J Edwards, S McCracken, ...
EMBO molecular medicine 4 (8), 776-790, 2012
Mandates: Cancer Research UK
Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation
K Mardilovich, M Gabrielsen, L McGarry, C Orange, R Patel, E Shanks, ...
Molecular cancer therapeutics 14 (1), 246-258, 2015
Mandates: US National Institutes of Health, Cancer Research UK
Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer
R Patel, EA Brzezinska, P Repiscak, I Ahmad, E Mui, M Gao, A Blomme, ...
Cancer Research 80 (3), 576-590, 2020
Mandates: Cancer Research UK, Prostate Cancer UK
Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment
LK Rushworth, K Hewit, S Munnings-Tomes, S Somani, D James, ...
British journal of cancer 122 (4), 517-527, 2020
Mandates: UK Biotechnology and Biological Sciences Research Council, Cancer Research …
Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis
CJ Loveridge, EJ Mui, R Patel, EH Tan, I Ahmad, M Welsh, J Galbraith, ...
Cancer research 77 (12), 3158-3168, 2017
Mandates: Cancer Research UK, Prostate Cancer UK
Sprouty2 loss‐induced IL 6 drives castration‐resistant prostate cancer through scavenger receptor B1
R Patel, J Fleming, E Mui, C Loveridge, P Repiscak, A Blomme, V Harle, ...
EMBO Molecular Medicine 10 (4), e8347, 2018
Mandates: Cancer Research UK, UK Medical Research Council, National Institute for …
An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism
M Nacke, E Sandilands, K Nikolatou, Á Román-Fernández, S Mason, ...
Nature Communications 12 (1), 1623, 2021
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer
LK Rushworth, V Harle, P Repiscak, W Clark, R Shaw, H Hall, M Bushell, ...
Life science alliance 3 (12), 2020
Mandates: UK Biotechnology and Biological Sciences Research Council, Cancer Research UK
Loss of N‐WASP drives early progression in an Apc model of intestinal tumourigenesis
HT Morris, L Fort, HJ Spence, R Patel, DF Vincent, JH Park, SB Snapper, ...
The Journal of Pathology 245 (3), 337-348, 2018
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression
R Patel, CA Ford, L Rodgers, LK Rushworth, J Fleming, E Mui, T Zhang, ...
Cancer Research 82 (14), 2565-2575, 2022
Mandates: Cancer Research UK
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
A Blomme, C Peter, E Mui, G Rodriguez Blanco, N An, LM Mason, ...
EMBO Molecular Medicine 14 (3), e14764, 2022
Mandates: Cancer Research UK, UK Engineering and Physical Sciences Research Council …
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration
CJ Loveridge, S Slater, KJ Campbell, NA Nam, J Knight, I Ahmad, ...
Oncogene 39 (8), 1797-1806, 2020
Mandates: National Health and Medical Research Council, Australia, Cancer Research UK …
Publication and funding information is determined automatically by a computer program